A potent tumor-selective ERK pathway inactivator with high therapeutic index

Author:

Zuo Zehua1ORCID,Liu Jie12ORCID,Sun Zhihao1,Silverstein Rachel1,Zou Meijuan1,Finkel Toren12,Bugge Thomas H3,Leppla Stephen H4ORCID,Liu Shihui15ORCID

Affiliation:

1. Aging Institute of University of Pittsburgh and University of Pittsburgh Medical Center , Pittsburgh, PA 15219, USA

2. Division of Cardiology, Department of Medicine, University of Pittsburgh School of Medicine , Pittsburgh, PA 15219, USA

3. Proteases and Tissue Remodeling Section, National Institute of Dental and Craniofacial Research, National Institutes of Health , Bethesda, MD 20892, USA

4. Microbial Pathogenesis Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MD 20892, USA

5. Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine , Pittsburgh, PA 15219, USA

Abstract

Abstract FDA-approved BRAF and MEK small molecule inhibitors have demonstrated some level of efficacy in patients with metastatic melanomas. However, these “targeted” therapeutics have a very low therapeutic index, since these agents affect normal cells, causing undesirable, even fatal, side effects. To address these significant drawbacks, here, we have reengineered the anthrax toxin-based protein delivery system to develop a potent, tumor-selective MEK inactivator. This toxin-based MEK inactivator exhibits potent activity against a wide range of solid tumors, with the highest activity seen when directed toward tumors containing the BRAFV600E mutation. We demonstrate that this reengineered MEK inactivator also exhibits an extremely high therapeutic index (>15), due to its in vitro and in vivo activity being strictly dependent on the expression of multiple tumor-associated factors including tumor-associated proteases matrix metalloproteinase, urokinase plasminogen activator, and anthrax toxin receptor capillary morphogenesis protein-2. Furthermore, we have improved the specificity of this MEK inactivator, restricting its enzymatic activity to only target the ERK pathway, thereby greatly diminishing off-target toxicity. Together, these data suggest that engineered bacterial toxins can be modified to have significant in vitro and in vivo therapeutic effects with high therapeutic index.

Funder

National Institutes of Health

National Institute of Dental and Craniofacial Research

Publisher

Oxford University Press (OUP)

Reference49 articles.

1. Oncogenic signaling pathways in The Cancer Genome Atlas;Sanchez-Vega;Cell,2018

2. Targeting RAS-ERK signalling in cancer: promises and challenges;Samatar;Nat Rev Drug Discov,2014

3. Trametinib: a MEK inhibitor for management of metastatic melanoma;Lugowska;Onco Tar Ther,2015

4. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma;Welsh;Ther Adv Med Oncol,2015

5. Biochemistry and cell signaling taught by bacterial effectors;Cui;Trends Biochem Sci,2011

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3